{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T18:34:34Z","timestamp":1780079674562,"version":"3.54.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372814"],"award-info":[{"award-number":["81372814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773103"],"award-info":[{"award-number":["81773103"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572848"],"award-info":[{"award-number":["81572848"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81772877"],"award-info":[{"award-number":["81772877"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81425018"],"award-info":[{"award-number":["81425018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81672868"],"award-info":[{"award-number":["81672868"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81602371"],"award-info":[{"award-number":["81602371"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010453","name":"National Development and Reform Commission","doi-asserted-by":"crossref","award":["2016YFC0902003"],"award-info":[{"award-number":["2016YFC0902003"]}],"id":[{"id":"10.13039\/501100010453","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100007390","name":"Instituto Nacional de Ci\u00eancia e Tecnologia Centro de Estudos das Adapta\u00e7\u00f5es da Biota Aqu\u00e1tica da Amaz\u00f4nia","doi-asserted-by":"crossref","award":["2017YFC1309003"],"award-info":[{"award-number":["2017YFC1309003"]}],"id":[{"id":"10.13039\/501100007390","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the National Key R&D Program of China","award":["2017YFC0908500"],"award-info":[{"award-number":["2017YFC0908500"]}]},{"name":"National Key Basic Research Program of China","award":["2013CB910304"],"award-info":[{"award-number":["2013CB910304"]}]},{"name":"Special Support Plan of Guangdong Province","award":["2014TX01R145"],"award-info":[{"award-number":["2014TX01R145"]}]},{"name":"PhD Start-up Fund of Natural Science Foundation of Guangdong Province","award":["2016A030310221"],"award-info":[{"award-number":["2016A030310221"]}]},{"name":"Cultivation Foundation for Junior Teachers in Sun Yat-sen University","award":["16ykpy28"],"award-info":[{"award-number":["16ykpy28"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-5192-x","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T10:42:44Z","timestamp":1545302564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Sai-Lan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Song","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-Xin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Feng","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Jun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Nan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Jie","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Chong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Quan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Qiang","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,20]]},"reference":[{"issue":"5","key":"5192_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.5732\/cjc.009.10329","volume":"29","author":"JT Wee","year":"2010","unstructured":"Wee JT, Ha TC, Loong SL, Qian CN. Is nasopharyngeal cancer really a \"Cantonese cancer\"? Chin J Cancer. 2010;29(5):517\u201326.","journal-title":"Chin J Cancer"},{"issue":"3","key":"5192_CR2","first-page":"172","volume":"75","author":"G Choa","year":"1967","unstructured":"Choa G. Nasopharyngeal carcinoma. Some observations on the clinical features and technique of examination. Pac Med Surg. 1967;75(3):172\u20134.","journal-title":"Pac Med Surg"},{"issue":"3","key":"5192_CR3","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","volume":"104","author":"G Peng","year":"2012","unstructured":"Peng G, Wang T, Yang KY, Zhang S, Zhang T, Li Q, Han J, Wu G. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol. 2012;104(3):286\u201393.","journal-title":"Radiother Oncol"},{"issue":"17","key":"5192_CR4","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1016\/j.ejca.2015.08.006","volume":"51","author":"MX Zhang","year":"2015","unstructured":"Zhang MX, Li J, Shen GP, Zou X, Xu JJ, Jiang R, You R, Hua YJ, Sun Y, Ma J, et al. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: a 10-year experience with a large cohort and long follow-up. Eur J Cancer. 2015;51(17):2587\u201395.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5192_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/S0360-3016(02)02724-4","volume":"53","author":"N Lee","year":"2002","unstructured":"Lee N, Xia P, Quivey JM, Sultanem K, Poon I, Akazawa C, Akazawa P, Weinberg V, Fu KK. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002;53(1):12\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"5192_CR6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.radonc.2013.10.020","volume":"110","author":"X Sun","year":"2014","unstructured":"Sun X, Su S, Chen C, Han F, Zhao C, Xiao W, Deng X, Huang S, Lin C, Lu T. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities. Radiother Oncology. 2014;110(3):398\u2013403.","journal-title":"Radiother Oncology"},{"issue":"23","key":"5192_CR7","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1200\/JCO.2001.19.23.4305","volume":"19","author":"RL Hong","year":"2001","unstructured":"Hong RL, Ting LL, Ko JY, Hsu MM, Sheen TS, Lou PJ, Wang CC, Chung NN, Lui LT. Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001;19(23):4305\u201313.","journal-title":"J Clin Oncol"},{"issue":"2","key":"5192_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","volume":"27","author":"EP Hui","year":"2009","unstructured":"Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, Yu BK, Chiu SK, Kwan WH, Ho R, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242\u20139.","journal-title":"J Clin Oncol"},{"issue":"11","key":"5192_CR9","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1093\/annonc\/mdq783","volume":"22","author":"P Bossi","year":"2011","unstructured":"Bossi P, Orlandi E, Bergamini C, Locati LD, Granata R, Mirabile A, Parolini D, Franceschini M, Fallai C, Olmi P, et al. Docetaxel, cisplatin and 5-fluorouracil-based induction chemotherapy followed by intensity-modulated radiotherapy concurrent with cisplatin in locally advanced EBV-related nasopharyngeal cancer. Ann Oncol Med Oncol. 2011;22(11):2495\u2013500.","journal-title":"Ann Oncol Med Oncol"},{"key":"5192_CR10","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.12659\/MSM.906625","volume":"24","author":"J Chen","year":"2018","unstructured":"Chen J, Qi J, Yu B, Peng XH, Wang F, Tan JJ, Chen QQ, Peng XY, Zeng FF, Liu X. A retrospective study to compare five induction chemotherapy regimens prior to radiotherapy in the reduction of regional lymph node size in patients with nasopharyngeal carcinoma. Med Sci Mon. 2018;24:2562\u20138.","journal-title":"Med Sci Mon"},{"issue":"1","key":"5192_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40880-018-0283-2","volume":"38","author":"GY Liu","year":"2018","unstructured":"Liu GY, Lv X, Wu YS, Mao MJ, Ye YF, Yu YH, Liang H, Yang J, Ke LR, Qiu WZ, et al. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Cancer Commun (London, England). 2018;38(1):21.","journal-title":"Cancer Commun (London, England)"},{"key":"5192_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.oraloncology.2018.02.011","volume":"79","author":"H Peng","year":"2018","unstructured":"Peng H, Tang LL, Chen BB, Chen L, Li WF, Mao YP, Liu X, Zhang Y, Liu LZ, Tian L, et al. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal carcinoma: a big-data intelligence platform-based analysis. Oral Oncol. 2018;79:40\u20136.","journal-title":"Oral Oncol"},{"issue":"5","key":"5192_CR13","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1097\/00000421-199810000-00013","volume":"21","author":"AD Colevas","year":"1998","unstructured":"Colevas AD, Posner MR. Docetaxel in head and neck cancer: a review. Am J Clin Oncol. 1998;21(5):482\u20136.","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"5192_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1093\/oxfordjournals.annonc.a058903","volume":"5","author":"J Verweij","year":"1994","unstructured":"Verweij J, Clavel M, Chevalier B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol. 1994;5(6):495\u2013505.","journal-title":"Ann Oncol"},{"issue":"9","key":"5192_CR15","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1200\/JCO.2011.36.2079","volume":"30","author":"CM Kelly","year":"2012","unstructured":"Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, et al. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012;30(9):930\u20135.","journal-title":"J Clin Oncol"},{"issue":"1","key":"5192_CR16","first-page":"205","volume":"31","author":"NK Sharma","year":"2015","unstructured":"Sharma NK, Kumar V. Liposomal paclitaxel: recent trends and future perspectives. Int J Pharm Sci Rev Res. 2015;31(1):205\u201311.","journal-title":"Int J Pharm Sci Rev Res"},{"issue":"5","key":"5192_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1080\/10717540601098799","volume":"14","author":"T Yang","year":"2007","unstructured":"Yang T, Cui F-D, Choi M-K, Lin H, Chung S-J, Shim C-K, Kim D-D. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Delivery. 2007;14(5):301\u20138.","journal-title":"Drug Delivery"},{"issue":"4","key":"5192_CR18","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.7314\/APJCP.2013.14.4.2591","volume":"14","author":"X Xu","year":"2013","unstructured":"Xu X, Wang L, Xu H-Q, Huang X-E, Qian Y-D, Xiang J. Clinical comparison between paclitaxel liposome (Lipusu\u00ae) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev. 2013;14(4):2591\u20134.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"5192_CR19","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","volume":"16","author":"M Al-Sarraf","year":"1998","unstructured":"Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998;16(4):1310\u20137.","journal-title":"J Clin Oncol"},{"issue":"8","key":"5192_CR20","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/cncr.29208","volume":"121","author":"AW Lee","year":"2015","unstructured":"Lee AW, Ngan RK, Tung SY, Cheng A, Kwong DL, Lu TX, Chan AT, Chan LL, Yiu H, Ng WT, et al. Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 2015;121(8):1328\u201338.","journal-title":"Cancer"},{"issue":"2","key":"5192_CR21","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.radonc.2008.02.003","volume":"87","author":"A Lee","year":"2008","unstructured":"Lee A, Lau K, Hung W, Ng W, Lee M, Choi C, Chan C, Tung R, Cheng P, Yau T. Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma. Radiother Oncol. 2008;87(2):204\u201310.","journal-title":"Radiother Oncol"},{"key":"5192_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1471-2407-10-39","volume":"10","author":"S Lin","year":"2010","unstructured":"Lin S, Lu JJ, Han L, Chen Q, Pan J. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of 370 consecutive cases. BMC Cancer. 2010;10:39.","journal-title":"BMC Cancer"},{"issue":"11","key":"5192_CR23","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.5732\/cjc.009.10435","volume":"28","author":"Z Yu","year":"2009","unstructured":"Yu Z, Luo W, Zhou QC, Zhang QH, Kang DH, Liu MZ. Impact of changing gross tumor volume delineation of intensity-modulated radiotherapy on the dose distribution and clinical treatment outcome after induction chemotherapy for the primary locoregionally advanced nasopharyngeal carcinoma. Ai zheng = Aizheng = Chinese journal of cancer. 2009;28(11):1132\u20137.","journal-title":"Ai zheng = Aizheng = Chinese journal of cancer"},{"key":"5192_CR24","doi-asserted-by":"crossref","unstructured":"Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M: Paclitaxel and its evolving role in the Management of Ovarian Cancer. Biomed Res Int 2015, 2015:413076.","DOI":"10.1155\/2015\/413076"},{"issue":"15","key":"5192_CR25","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med. 1995;332(15):1004\u201314.","journal-title":"N Engl J Med"},{"issue":"5 Pt 2","key":"5192_CR26","first-page":"110s","volume":"17","author":"BR Goldspiel","year":"1997","unstructured":"Goldspiel BR. Clinical overview of the taxanes. Pharmacotherapy. 1997;17(5 Pt 2):110s\u201325s.","journal-title":"Pharmacotherapy"},{"issue":"9210","key":"5192_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/S0140-6736(00)02074-2","volume":"355","author":"J Crown","year":"2000","unstructured":"Crown J, O'Leary M. The taxanes: an update. Lancet (London, England). 2000;355(9210):1176\u20138.","journal-title":"Lancet (London, England)"},{"issue":"6","key":"5192_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.2174\/1567201811666140609154949","volume":"11","author":"C Nehate","year":"2014","unstructured":"Nehate C, Jain S, Saneja A, Khare V, Alam N, Dubey RD, Gupta PN. Paclitaxel formulations: challenges and novel delivery options. Curr Drug Deliv. 2014;11(6):666\u201386.","journal-title":"Curr Drug Deliv"},{"issue":"17","key":"5192_CR29","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","volume":"357","author":"MR Posner","year":"2007","unstructured":"Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17):1705\u201315.","journal-title":"N Engl J Med"},{"issue":"17","key":"5192_CR30","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","volume":"357","author":"JB Vermorken","year":"2007","unstructured":"Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17):1695\u2013704.","journal-title":"N Engl J Med"},{"issue":"2","key":"5192_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S1470-2045(10)70279-5","volume":"12","author":"JH Lorch","year":"2011","unstructured":"Lorch JH, Goloubeva O, Haddad RI, Cullen K, Sarlis N, Tishler R, Tan M, Fasciano J, Sammartino DE, Posner MR. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol. 2011;12(2):153\u20139.","journal-title":"Lancet Oncol"},{"issue":"7","key":"5192_CR32","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp007","volume":"101","author":"Y Pointreau","year":"2009","unstructured":"Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, Faivre S, Guerrif S, Alfonsi M, Calais G. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498\u2013506.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"5192_CR33","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","volume":"17","author":"Y Sun","year":"2016","unstructured":"Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, et al. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509\u201320.","journal-title":"Lancet Oncol"},{"key":"5192_CR34","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.2147\/IJN.S113723","volume":"11","author":"SS Hong","year":"2016","unstructured":"Hong SS, Choi JY, Kim JO, Lee MK, Kim SH, Lim SJ. Development of paclitaxel-loaded liposomal nanocarrier stabilized by triglyceride incorporation. Int J Nanomedicine. 2016;11:4465\u201377.","journal-title":"Int J Nanomedicine"},{"issue":"1\u20132","key":"5192_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0168-3659(99)00166-2","volume":"63","author":"P Crosasso","year":"2000","unstructured":"Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, Cattel L. Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Controlled Release. 2000;63(1\u20132):19\u201330.","journal-title":"J Controlled Release"},{"key":"5192_CR36","doi-asserted-by":"crossref","unstructured":"Huang ST, Wang YP, Chen YH, Lin CT, Li WS, Wu HC. Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol. Int J Oncol, 1117. 2018;53(3):1105.","DOI":"10.3892\/ijo.2018.4449"},{"issue":"1","key":"5192_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-017-3332-7","volume":"80","author":"T Aoyama","year":"2017","unstructured":"Aoyama T, Takano M, Miyamoto M, Yoshikawa T, Soyama H, Kato K, Ishibashi H, Iwahashi H, Nakatsuka M, Yajima I, et al. Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol. 2017;80(1):65\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"5192_CR38","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000450748","volume":"62","author":"T Ratanajarusiri","year":"2017","unstructured":"Ratanajarusiri T, Sriuranpong V, Sitthideatphaiboon P, Poovoravan N, Vinayanuwat C, Parinyanitikul N, Angspatt P, Thawinwisan W, Tanasanvimon S. A difference in the incidences of hypersensitivity reactions to original and generic Taxanes. Chemotherapy. 2017;62(2):134\u20139.","journal-title":"Chemotherapy"},{"key":"5192_CR39","doi-asserted-by":"crossref","unstructured":"Chen G, Sheng L, Du X. Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma. Cancer Chemother Pharmacol. 2018.","DOI":"10.1200\/JCO.2018.36.15_suppl.e20516"},{"issue":"8","key":"5192_CR40","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.biopha.2008.10.001","volume":"63","author":"Q Zhang","year":"2009","unstructured":"Zhang Q, Huang XE, Gao LL. A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. Biomed Pharmacother. 2009;63(8):603\u20137.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"5192_CR41","first-page":"305","volume":"36","author":"HY Wang","year":"2014","unstructured":"Wang HY, Zhang XR. Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer. Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae. 2014;36(3):305\u20138.","journal-title":"Zhongguo yi xue ke xue yuan xue bao Acta Academiae Medicinae Sinicae"},{"issue":"2","key":"5192_CR42","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/or.2014.3644","volume":"33","author":"RH Wang","year":"2015","unstructured":"Wang RH, Cao HM, Tian ZJ, Jin B, Wang Q, Ma H, Wu J. Efficacy of dual-functional liposomes containing paclitaxel for treatment of lung cancer. Oncol Rep. 2015;33(2):783\u201391.","journal-title":"Oncol Rep"},{"issue":"5","key":"5192_CR43","first-page":"379","volume":"37","author":"W Su","year":"2015","unstructured":"Su W, Zhang S, Li C, Hao X, Zhang J. Efficacy and safety analysis of paclitaxel liposome and docetaxel for the neoadjuvant chemotherapy of breast cancer. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2015;37(5):379\u201382.","journal-title":"Zhonghua zhong liu za zhi [Chinese journal of oncology]"},{"issue":"9","key":"5192_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.5414\/CP202568","volume":"54","author":"M Lu","year":"2016","unstructured":"Lu M, Wang T, Wang J. Effects of paclitaxel liposome and capecitabine in the treatment of advanced gastric cancer by clinical observation. Int J Clin Pharmacol Ther. 2016;54(9):693\u20137.","journal-title":"Int J Clin Pharmacol Ther"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-018-5192-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-5192-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T19:09:19Z","timestamp":1576782559000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-5192-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["5192"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-5192-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"19 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Clinical Research Committee of Sun Yat-sen University Cancer Center. Patients were required to provide written informed consent before enrolling in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"1279"}}